Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents A Prospective Cohort Study

L Raber, Michael Magro, GG Stefanini, B Kalesan, Ron van Domburg, Yoshinobu Onuma, P Wenaweser, Joost Daemen, B Meier, P Juni, PWJC (Patrick) Serruys, S Windecker

Research output: Contribution to journalArticleAcademicpeer-review

340 Citations (Scopus)


Background-Early-generation drug-eluting stents releasing sirolimus (SES) or paclitaxel (PES) are associated with increased risk of very late stent thrombosis occurring >1 year after stent implantation. It is unknown whether the risk of very late stent thrombosis persists with newer-generation everolimus-eluting stents (EES). Methods and Results-We assessed the risk of stent thrombosis in a cohort of 12 339 patients with unrestricted use of drug-eluting stents (3819 SES, 4308 PES, 4212 EES). Results are incidence rates per 100 person-years after inverse probability of treatment weighting to adjust for group differences. During follow-up of up to 4 years, the overall incidence rate of definite stent thrombosis was lower with EES (1.4 per 100 person-years) compared with SES (2.9; hazard ratio, 0.41; 95% confidence inte Conclusion-Current treatment with EES is associated with a lower risk of very late stent thrombosis compared with early-generation drug-eluting stents. (Circulation. 2012;125:1110-1121.)
Original languageUndefined/Unknown
Pages (from-to)1110-U108
Issue number9
Publication statusPublished - 2012

Research programs

  • EMC COEUR-09

Cite this